FIG 1.

RVFV MAbs display a range of binding and neutralization activities and target domains throughout Gn. (A) The ability of MAbs to neutralize RVFV was assessed by serial dilution of MAbs in an FRNT assay. (B) MAbs were also tested for their ability to bind Gn by RVFV-infected lysate ELISA. Means and standard deviations (SDs) from triplicates are reported for both FRNT and ELISA data. (C) Schematic of the RVFV Gn protein with MAbs mapped to the domain required for binding, as determined through Western blot analysis of truncated Gn constructs. (D) MAbs were mapped to specific epitopes by Gn peptide ELISA.